ReviewMemorias do Instituto Oswaldo Cruz2015
New insights on the development of fungal vaccines: from immunity to recent challenges.
Review in Memorias do Instituto Oswaldo Cruz, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 69 citations in OpenAlex.
- Glycan microarray analysis ofProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Promising immunotherapeutic targets for treating candidiasis.Frontiers in cellular and infection microbiology · 2024Review
- A 14-Year Cohort of Candidemia in the Pediatric Population in a Tertiary Center in Jerusalem: Clinical Characteristics, Antifungal Susceptibility, and Risk Factors for Mortality.Journal of fungi (Basel, Switzerland) · 2023Article
- Superficial Dermatophytosis across the World's Populations: Potential Benefits from Nanocarrier-Based Therapies and Rising Challenges.ACS omega · 2023Review
- Review
- Intestinal bacteria-a powerful weapon for fungal infections treatment.Frontiers in cellular and infection microbiology · 2023Review
- Harnessing the Immune Response to Fungal Pathogens for Vaccine Development.Annual review of microbiology · 2022Review
- Genome-wide scan for potential CD4+ T-cell vaccine candidates inFrontiers in medicine · 2022Article
- Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?Infection · 2021Review
- The Role of B-Cells and Antibodies againstVaccines · 2021Review
- Prophylaxis and Therapeutic Ability of Inactivated Dermatophytic Vaccine Against Dermatophytosis in the Rabbits as an Animal ModelTurkish journal of pharmaceutical sciences · 2021Article
- Review
- Vaccine-Induced Immunological Memory in Invasive Fungal Infections - A Dream so Close yet so Far.Frontiers in immunology · 2021Review
- Application of Machine Learning Classifier toFrontiers in cellular and infection microbiology · 2021Article
- Immunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies.Journal of fungi (Basel, Switzerland) · 2020Review
- Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response.Frontiers in immunology · 2020Review
- Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections.Frontiers in cellular and infection microbiology · 2020Review
- A Heat-KilledmBio · 2019Article
- TargetingFrontiers in microbiology · 2019Article
- Special Issue "Journal of fungi (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Fungal infections are emerging as a major problem in part due to high mortality associated with systemic infections, especially in the case of immunocompromised patients. With the development of new treatments for diseases such as cancer and the acquired immune deficiency syndrome pandemic, the number of immunosuppressed patients has increased and, as a consequence, also the number of invasive fungal infections has increased. Several studies have proposed new strategies for the development of effective fungal vaccines. In addition, better understanding of how the immune system works against fungal pathogens has improved the further development of these new vaccination strategies. As a result, some fungal vaccines have advanced through clinical trials. However, there are still many challenges that prevent the clinical development of fungal vaccines that can efficiently immunise subjects at risk of developing invasive fungal infections. In this review, we will discuss these new vaccination strategies and the challenges that they present. In the future with proper investments, fungal vaccines may soon become a reality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.